Progress of inhibitors of 3-hydroxy-3-methylglutary coenzyme A reductase against hypertension

Chinese Journal of Clinical Rehabilitation

Volumn 7, Issue 30, 2003, Pages 4130-4131

  He, Ju Ying ^a   Tang, Min ^a   Zang, Lei ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MEVINOLIN; MONACOLINK; PRAVASTATIN; PROTEIN P21; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ENZYME INHIBITION; HUMAN; HYPERTENSION; REVIEW; RNA ANALYSIS; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

EID: 2442533024     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterocemia. N Engl J Med 1995; 333: 1301-5
2. Farnier M, Davignon S. Current and fature treatment of hyperlipidmi: the role of statins. Am J Caodiol 1998; 84(4B): 3-10
3. Endo, A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitions of cholesterogenesis produced penicillium citrinum. J Antibiot 1976; 29 (12): 1346-8
4. Endo A, Monacolin K. A new hypocholesterolemic agent produced by a Monascus Species. J Antibiot 1979; 32(8): 852-4
5. Albert AW. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in nomal animals. Proc Natl Acad Sci USA 1980; 77(10): 3957-62
6. Sevizawa N, Nakagawa K, Hamanoka K. Microbial hydroxylation of MC-236B (Compactin) and Monacolink (MB-530B). J Antibiot 1983; 36(5)36: 604-7
7. Lea AP, McTavish D, Atovastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Durgs 1997; 53(5): 828-7
8. Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The cerivastatin study crroup. Cerivastatin gemfibrozil hyperlipidemia treatment. Am J Cardid 1998; 82(411): 47J-50
9. Dart A, Jerum G, Nicholson G, et al. A multicenter, double-blind, one- year study comparing safety and efficacy of atovastatin versus simvastatin in patients with hypercholesterolemic. Am J Cardiol 1997; 80(1): 39-44
10. Martinez-Gonzalez J, vinals M, Vidal F, et al. Meralonete depriation inperis IGF-I/insulin signaling in human vastular smooth musche cells. Atherosderosis 1997; 35(2): 213-23
11. Aviram M, Hussein O, Rosenblat M, et al. Interaction of platelets, macrophages, and Lipoproteins in hypercholeseerolemia: ontiatherogenle effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31(1): 39-45
12. Chinese source. 1999, 27(1): 56-60
13. Stein B. Cerivastatin in primary heperlipidemia: amulticenter analysis of efficacy and safety. Am J Cardiol 1998; 82(4B): 40-5
14. Chinese source. 2001, 5 (12): 49-50
15. Chinese source. 1997, 6(1): 44-5
16. Yui Y, Kawai C, Hosoda S. Pravastatin restenosis trial after percutaneous transluminal coronary angioplasty. Choleserol reduction rate determines the restenosis rate. Ann N Y Acal Sci 1995; 748: 208-12
17. Smit JW, Wijinne, HG, Schobben F, et al. Effects of acchohol and Fluvastatin on Lipid metabolism and hepatic function. Ann Intern Med 1995; 122(3): 678-802